PD1A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sales MomentumImproving sales momentum, particularly in the second half, indicates better underlying demand and execution across Ansell’s PPE markets. Growth in strategic healthcare, U.S., and cleanroom activities can support a more resilient revenue base and increase the contribution of higher-value products over coming quarters.
Margin ExpansionHigher EBIT margins combined with recurring productivity savings strengthen the economics of Ansell’s business beyond simple volume growth. Sustained operational improvements and favorable product mix can provide greater earnings resilience, support reinvestment, and help protect profitability when input costs or demand conditions fluctuate.
Cash Generation And LiquidityStrong cash conversion and improved leverage give Ansell meaningful financial flexibility. The combination of internally generated cash, lower net debt relative to EBITDA, and available liquidity supports strategic investment, shareholder returns, and the ability to absorb operational volatility without relying heavily on new financing.
Bears Say
Uneven Revenue And Volume TrendAlthough second-half demand recovered, slightly lower full-year volumes and an uneven multi-year revenue path show that growth has not been consistently broad-based. This may make future expansion more dependent on pricing, mix, and execution, increasing the risk that revenue momentum moderates after recent improvements.
Input-Cost And Geopolitical VolatilityVolatile commodity and geopolitical costs can pressure gross margins and complicate pricing decisions across Ansell’s global PPE operations. Management has passed through some costs, but rapid reversals or delayed recovery could still reduce profitability and make earnings less predictable over the next several quarters.
Transformation Execution RiskERP modernization and broader transformation initiatives may eventually improve efficiency, but their multi-year timetable creates execution and cost risk before benefits are fully realized. Delays or additional implementation demands could absorb management attention and defer the productivity gains expected to support margins.
Ansell News
PD1A FAQ
What was Ansell’s price range in the past 12 months?
Currently, no data Available
What is Ansell’s market cap?
Ansell’s market cap is CHF3.64B.
When is Ansell’s upcoming earnings report date?
Ansell’s upcoming earnings report date is Feb 22, 2027 which is in 114 days.
How were Ansell’s earnings last quarter?
Ansell released its earnings results on Aug 23, 2026. The company reported CHF0.679 earnings per share for the quarter, beating the consensus estimate of CHF0.64 by CHF0.039.
Is Ansell overvalued?
According to Wall Street analysts Ansell’s price is currently Undervalued.
Does Ansell pay dividends?
Ansell does not currently pay dividends.
What is Ansell’s EPS estimate?
Ansell’s EPS estimate is 0.63.
How many shares outstanding does Ansell have?
Ansell has 140,313,830 shares outstanding.
What happened to Ansell’s price movement after its last earnings report?
Ansell reported an EPS of CHF0.679 in its last earnings report, beating expectations of CHF0.64. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ansell?
Currently, no hedge funds are holding shares in CH:PD1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ansell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF22.74 (― Upside)
CHF22.74 (― Upside)
Insider Transactions
Bought Shares
Worth CHF165.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.02%
12-Months-Change
Fundamentals
Return on Equity
10.52%
Trailing 12-Months
Asset Growth
2.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ansell
Ansell Limited is a global enterprise that conceptualizes, innovates, and produces protective equipment for various industries across numerous regions, including Asia Pacific, Europe, the Middle East, Africa, the Americas, and the Caribbean. The company's operations are divided into two principal divisions: Healthcare and Industrial. The Healthcare division focuses on crafting and distributing products such as surgical, single-use, and examination gloves, alongside specialized cleanroom and sterile gloves and apparel. These offerings cater to a diverse clientele including medical facilities, surgical clinics, dental offices, veterinary practices, emergency services, research laboratories, and pharmaceutical and life science firms. Conversely, the Industrial segment provides hand and chemical protective gear designed for a wide array of demanding applications, from the automotive, chemical, and metal fabrication sectors to machinery, food processing, construction, mining, oil and gas industries, and first responders. Established in 1893 and headquartered in Richmond, Australia, the company was initially known as Pacific Dunlop Limited before rebranding to Ansell Limited in 2002. P. D. Holdings Pty. Ltd. currently operates as a subsidiary of Ansell Limited.
PD1A Company Deck
PD1A Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear majority of positive operational and financial outcomes — double-digit EPS growth, higher margins, strong cash conversion, U.S. and Cleanroom-led sales momentum, recurring cost savings (APIP $50M) and improved balance sheet metrics. Management also acknowledged and proactively managed notable headwinds (Middle East cost inflation, U.S. tariffs, commodity volatility, FX hedge losses and non‑cash impairments), and provided a constructive FY'27 EPS guidance range of $1.58–$1.70 with assumptions of continued volume/price momentum and ~$9M FX tailwind. On balance the positives — strong execution, margin expansion, cash generation and concrete operational improvements — outweigh the transient and manageable risks cited.View all CH:PD1A earnings summariesPD1A Stock 12 Month Forecast
Average Price Target
―Nanosonics Limited
―
Medical Developments International Limited
―
Trajan Group Holdings Ltd
―
CleanSpace Holdings Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―